Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0D6LF
|
||||
Former ID |
DIB006819
|
||||
Drug Name |
PD-156
|
||||
Synonyms |
PD-156; PD-503; PF-152; PF-212; PF-80; MMP-13 inhibitors (inflammation); MMP-13 inhibitors (inflammation), Pfizer
|
||||
Company |
Pfizer Inc
|
||||
Structure |
Download2D MOL |
||||
Canonical SMILES |
C1COCCC1(S(=O)(=O)c1ccc(cc1)OCCCn1c(nnn1)c1ccc(cn1)C)C(<br />=O)NO
|
||||
CAS Number |
CAS 609816-98-0
|
||||
Target and Pathway | |||||
Target(s) | Collagenase 3 | Target Info | Inhibitor | [528284], [536172] | |
NetPath Pathway | IL1 Signaling Pathway | ||||
PANTHER Pathway | Alzheimer disease-presenilin pathway | ||||
Plasminogen activating cascade | |||||
Pathway Interaction Database | Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | ||||
References | |||||
Ref 528284 | Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial. J Am Coll Cardiol. 2006 Jul 4;48(1):15-20. Epub 2006 Jun 21. | ||||
Ref 536172 | Selective matrix metalloproteinase inhibition attenuates progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure. Am J Physiol Heart Circ Physiol. 2006 Jun;290(6):H2522-7. Epub 2006 Jan 20. | ||||
Ref 528284 | Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial. J Am Coll Cardiol. 2006 Jul 4;48(1):15-20. Epub 2006 Jun 21. | ||||
Ref 536172 | Selective matrix metalloproteinase inhibition attenuates progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure. Am J Physiol Heart Circ Physiol. 2006 Jun;290(6):H2522-7. Epub 2006 Jan 20. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.